HP-β-CD [128446-35-5]
Referência T19609-10g
Tamanho : 10g
Marca : TargetMol
HP-β-CD
(Synonyms: Hydroxypropyl-β-cyclodextrin, Hydroxypropyl betadex) Copy Product Info
HP-β-CD (Hydroxypropyl betadex) is a water-soluble cyclodextrin derivative obtained by hydroxypropylation of β-cyclodextrin. HP-β-CD serves as a drug delivery carrier that enhances stability and bioavailability.
Cas No. 128446-35-5
For research use only—not for human use. No sales to individuals. Use as intended only.
Select Batch
Purity:98%
Color:White
Product Introduction
Bioactivity
Chemical Properties
Storage & Solubility Information
| Description | HP-β-CD (Hydroxypropyl betadex) is a water-soluble cyclodextrin derivative obtained by hydroxypropylation of β-cyclodextrin. HP-β-CD serves as a drug delivery carrier that enhances stability and bioavailability. |
| Targets & IC50 | leukemia cell:3.86–10.09 mM, SKOV3 cells:1.94 μM |
| In vitro | Methods: Cheliensisin A native compound and its HP-β-CD inclusion complex (compound:HP-β-CD molar ratio 1:2) were added to SW1116, SMMC-7721, and HEK293T cells. Drug concentration gradient: 0–100 μM. Treatment duration: 24 hours. Cell viability was assessed using the MTT assay. Results: The inclusion complex significantly enhanced cytotoxicity against tumor cells. For SW1116 cells, the IC₅₀ of the cheliensisin A inclusion complex decreased from 93.2 to 51.4 μM. The inclusion complex also exhibited increased toxicity toward HEK293T cells. [1] Methods: Human aortic smooth muscle cells (HASMCs) were treated with HP-β-CD (6, 8, 10 mg/mL) for 24 h, followed by Western blot analysis of apoptosis markers. Results: HP-β-CD dose-dependently inhibited VSMC apoptosis. [2] |
| In vivo | Methods: Male C57BL/6J mice were used in a PCSK9/angiotensin II (AngII)-induced AAA model. HP-β-CD (200 µl/mouse) was administered intraperitoneally twice weekly starting at the initiation of AngII infusion, continuing for 4 weeks. Results: HP-β-CD significantly reduced the maximum diameter of the abdominal aorta and the incidence of AAA, while also mitigating elastin degradation and VSMC apoptosis. [2] |
| Synonyms | Hydroxypropyl-β-cyclodextrin, Hydroxypropyl betadex |
| Molecular Weight | 1541.547 |
| Formula | C63H112O42 |
| Cas No. | 128446-35-5 |
| Smiles | CC(O)COC[C@@H]1O[C@H]2O[C@H]3[C@H](COCC(C)O)O[C@@H](O[C@H]4[C@H](COCC(C)O)O[C@@H](O[C@H]5[C@H](COCC(C)O)O[C@@H](O[C@H]6[C@H](COCC(C)O)O[C@@H](O[C@H]7[C@H](COCC(C)O)O[C@@H](O[C@H]8[C@H](COCC(C)O)O[C@@H](O[C@@H]1[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]8O)[C@@H](O)[C@@H]7O)[C@@H](O)[C@@H]6O)[C@@H](O)[C@@H]5O)[C@@H](O)[C@@H]4O)[C@@H](O)[C@@H]3O |
| Relative Density. | 1.05 g/cm3 at 20.3℃ |
| Storage | Keep away from moisture Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||
| Solubility Information | DMSO: 45.00 mg/mL (29.19 mM), Sonication is recommended.  H2O: 50.00 mg/mL (32.43 mM), Sonication is recommended. | |||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween-80+45% Saline: 2 mg/mL (1.3 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||
DMSO/H2O
Note : The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density. | ||||||||||||||||||||||||||